BIFUNCTIONAL MOLECULE BINDING TO HUMAN TGFß AND PD-L1, AND USE THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 16, 2024
app pub date -
Mar 11, 2022
filing date -
Mar 12, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided are a bifunctional molecule capable of binding to human transforming growth factor β (TGFβ) and human programmed death-ligand 1 (PD-L1), a pharmaceutical composition comprising the same, and use thereof treating cancer. The bifunctional molecule has high affinity for PD-L1, can significantly promote the secretion of IL-2 and IFN-γ, enhances T cell immune responses, and can block TGFβ with high specificity, and thus can be used for treating cancer. Also provided is a monoclonal antibody or an antigen-binding fragment thereof binding to human PD-L1.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully